GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies

Researchers reviewed animal experiments and human studies of GLP-1 receptor agonists, medicines that mimic a gut hormone and help with weight loss. Sarcopenia means losing muscle strength and muscle mass with age. Animal studies suggest these medicines may protect muscle, but human studies often find that some weight lost is lean mass, which includes muscle and other tissues. The human evidence is difficult to interpret because many studies used body scans rather than tests of strength or physical ability.

What this means for you: This review does not prove that GLP-1 medicines cause harmful muscle loss, but it also cannot rule it out. People using them should discuss adequate protein, strength exercise, and muscle monitoring with a healthcare professional rather than avoiding treatment based on headlines alone.